OSX2:F:F-Ossiam Lux - Ossiam US Minimum Variance NR (EUR)

ETF | Others |

Last Closing

USD 283.5

Change

-1.90 (-0.67)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-25 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

-0.08 (-0.28%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

N/A

USD 109.59B
SXR8:F iShares Core S&P 500 UCITS ETF..

+1.28 (+0.24%)

USD 96.22B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.17 (-0.32%)

USD 91.00B
SXRZ:F iShares VII PLC - iShares Nikk..

N/A

USD 54.70B
XDNY:F Xtrackers MSCI Japan ESG Scree..

N/A

USD 52.21B
VUAA:F Vanguard S&P 500 UCITS Acc

+0.19 (+0.19%)

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

-0.08 (-0.08%)

USD 51.63B
XJSE:F Xtrackers II - Japan Governmen..

-0.03 (-0.35%)

USD 40.38B
0ZC:F Zscaler Inc

-2.26 (-1.45%)

USD 37.92B

ETFs Containing OSX2:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.92% 73% C 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.92% 70% C- 61% D-
Trailing 12 Months  
Capital Gain 14.29% 58% F 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.29% 54% F 55% F
Trailing 5 Years  
Capital Gain 34.78% 58% F 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 34.78% 58% F 50% F
Average Annual (5 Year Horizon)  
Capital Gain 7.06% 63% D 63% D
Dividend Return 7.06% 61% D- 56% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 9.88% 67% D+ 89% A-
Risk Adjusted Return 71.48% 81% B- 85% B
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike